glp-1 nobel prize agonists have transformed life for many people with type 2 diabetes and obesity. The 2025 Breakthrough honors Daniel Drucker, Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov Harvard Medical School Researcher Wins
Description
For diabetic retinopathy, the evidence was nuanced, indicating potential long-term neurovascular protection but also a risk of transient early worsening
These medications are not indicated for type 1 diabetes or diabetic ketoacidosis
It remains unclear whether these neural antiinflammatory actions of GLP-1 medicines require microglial GLP-1R activity
His HbA1c is still above target at 8.4%, and the mean postprandial blood glucose is 232 mg/dL
This allows customers to try the product risk-free and determine if it fits their goals
